| Line Item | 2025-10-31 | Q/Q | Y/Y |
|---|---|---|---|
| Revenue | $184.2M | — | +32.9% |
| Cost of Revenue | $77.5M | — | +65.8% |
| Gross Profit | $106.6M | — | +16.2% |
| R&D Expense | $262.7M | — | +321.0% |
| SG&A Expense | $141.0M | — | +709.0% |
| Operating Income | -$447.0M | — | -730.3% |
| Income Tax | $3.1M | — | +708.5% |
| Net Income | -$453.1M | -401.7% | -540.5% |
| EPS (Basic) | -$1.85 | — | -156.9% |
| EPS (Diluted) | -$1.85 | — | -156.9% |
| Line Item | 2025-10-31 | Q/Q | Y/Y |
|---|---|---|---|
| Cash & Equivalents | $984.7M | — | — |
| Short-term Investments | $168.3M | — | — |
| Accounts Receivable | $131.5M | — | — |
| Inventory | $5.4M | — | — |
| Current Assets | $1.40B | — | — |
| Total Assets | $1.72B | — | — |
| Line Item | 2025-10-31 | Q/Q | Y/Y |
|---|---|---|---|
| Operating Cash Flow | $19.9M | — | — |
| Capital Expenditures | $9.6M | — | — |
| Investing Cash Flow | -$98.6M | — | — |
| Financing Cash Flow | $897.3M | — | — |
| Free Cash Flow | $10.4M | — | — |
| Current Liabilities |
| $603.0M |
| — |
| — |
| Total Liabilities | $1.56B | — | — |
| Stockholders' Equity | $151.0M | +124.7% | +134.1% |